Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Volition Advances Nu.Q® NETs Platform Towards Commercialization

Thursday, July 30, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: VolitionRx Limited has announced advancements in its Nu.Q® NETs platform, which is positioned as a potential breakthrough in sepsis management. The company highlighted substantial clinical and scientific data supporting the product's effectiveness. The Nu.Q® H3.1 operates within a significant $3.8 billion market, indicating strong commercial potential.

Market Sentiment Analysis

POSITIVE FACTORS

  • Nu.Q® H3.1 shows promise as a game changer in sepsis management.
  • The product operates within a substantial $3.8 billion market.
  • Significant clinical and scientific evidence supports its efficacy.

Full Press Release Details

Consistent international data positions Nu.Q® H3.1 as a potential "game changer" in sepsis management within a $3.8 billion addressable market

HENDERSON, Nev., July 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive update highlighting the significant clinical and scientific evidence amassed for its Nu.Q® NETs product. It also issued a video featuring Critical Care Lead and Medical Consultant to Volition, Dr Andrew Retter, who explains the scientific and clinical significance of these findings.

Mr. Gael Forterre, Chief Commercial Officer, Volition commented:

Frequently Asked Questions

What is the Nu.Q® NETs platform?

The Nu.Q® NETs platform is a product by VolitionRx aimed at improving sepsis management.

What market does Nu.Q® H3.1 target?

Nu.Q® H3.1 operates within a $3.8 billion addressable market.

Who provided insights on the Nu.Q® product?

Dr. Andrew Retter, Critical Care Lead and Medical Consultant, discussed its significance.

What evidence supports Nu.Q® H3.1?

VolitionRx has amassed significant clinical and scientific evidence for Nu.Q® H3.1.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare VolitionRx Nu.Q® H3.1 sepsis management clinical evidence biopharma
Last updated: Jul 30, 2026

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~0 mo
High dilution risk